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Abstract 
Carbamoyl phosphate synthetase 1 deficiency (CPS1D) is an inborn error of the urea 
cycle that is due to mutations in the CPS1 gene. In the first large repertory of mutations 
found in CPS1D, a small CPS1 domain of unknown function (called the UFSD) was 
found to host missense changes with high frequency, despite the fact that this domain 
does not host substrate-binding or catalytic machinery. We investigate here by in vitro 
expression studies using baculovirus/insect cells the reasons for the prominence of the 
UFSD in CPS1D, as well as the disease-causing roles and pathogenic mechanisms of 
the mutations affecting this domain. All but three of the 18 missense changes found thus 
far mapping in this domain in CPS1D patients drastically decreased the yield of pure 
CPS1, mainly because of decreased enzyme solubility, strongly suggesting misfolding 
as a major determinant of the mutations negative effects. In addition, the majority of the 
mutations also decreased from modestly to very drastically the specific activity of the 
fraction of the enzyme that remained soluble and that could be purified, apparently 
because they decreased Vmax. Substantial although not dramatic increases in Km values 
for the substrates or for N-acetyl-L-glutamate were observed for only five mutations. 
Similarly, important thermal stability decreases were observed for three mutations. The 
results indicate a disease-causing role for all the mutations, due in most cases to the 
combined effects of the low enzyme level and the decreased activity. Our data strongly 
support the value of the present expression system for ascertaining the disease-causing 
potential of CPS1 mutations, provided that the CPS1 yield is monitored. The observed 
effects of the mutations have been rationalized on the basis of an existing structural 
model of CPS1. This model shows that the UFSD, which is in the middle of the 1462-
residue multidomain CPS1 protein, plays a key integrating role for creating the CPS1 
multidomain architecture leading us to propose here a denomination of "Integrating 
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Domain" for this CPS1 region. The majority of these 18 mutations distort the interaction 
of this domain with other CPS1 domains, in many cases by causing improper folding of 
structural elements of the Integrating Domain that play key roles in these interactions.  
 
 
 
Key words: urea cycle diseases; CPS1 deficiency; hyperammonemia; inborn errors; 
CPS 1 structure; site-directed mutagenesis 
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1. Introduction 
 Primary CPS1 deficiency (CPS1D; MIM #237300), a recessively inherited urea 
cycle disease leading to frequently fatal hyperammonemia [1,2], is due to mutations in 
the CPS1 gene. This gene, located in 2q35 [3] and being composed of 38 exons and 37 
introns [4-6], with 4,500 coding nucleotides, encodes a 1500-residue proenzyme [7] that 
is synthesized in hepatocytes and enterocytes [8,9], and which, upon internalization to 
the mitochondrial matrix, yields after cleavage of its N-terminal 38 amino acids, the 
mature 1,462-amino acid multidomain (Fig. 1A) CPS1 protein [10-12] [E.C. 6.3.4.16]. 
 CPS1 catalyzes the first step of the urea cycle (2ATP + NH3 + HCO3-→ 2ADP + 
HPO42- + NH2CO2PO32-) [13], converting ammonia to carbamoyl phosphate (CP), a 
compound that is utilized by ornithine transcarbamylase (OTC) to make citrulline in the 
second reaction of the urea cycle. The three-step CPS1 reaction (Fig. 1B) includes two 
analogous ATP-dependent phosphorylations, of bicarbonate and carbamate, and an 
intervening step of carbamate synthesis from carboxyphosphate and ammonia [13]. To 
be active, CPS1 requires the presence of an essential allosteric activator, N-acetyl-L-
glutamate (NAG) [10,14,15], made by NAG synthase from glutamate and acetyl-
coenzyme A [16]. The rate of NAG synthesis heavily depends on glutamate 
concentration [17], and therefore NAG represents a switch for CPS1 activity, which is 
turned off when glutamate levels decrease, thus preventing excessive nitrogen draining 
by the urea cycle from an already low amino acid pool [18,19]. NAG activation is a 
unique property of CPS1 (and to a lesser extent of the piscine CPS1 homologue CPSIII) 
[20], not being shared by other CPSs, all of which are active in the absence of effectors 
and are insensitive to NAG [13,21,22]. NAG activation involves a functionally crucial 
cross-talk between NAG and phosphorylation sites. Thus, NAG vastly increases the 
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apparent affinity of CPS1 for ATP and for its ionic activators K+ and Mg2+ [15] and, 
conversely, ATP, K+ and Mg2+ greatly increase CPS1 affinity for NAG [23]. 
 The complexities of the CPS1 reaction and regulation are backed by a 
sophisticated multidomain protein machinery [13], that is still imperfectly characterized, 
since the crystal structure of CPS1 has not been determined (except for its ∼15 kDa C-
terminal domain, representing only ∼10% of the entire molecule) [24,25]. Nevertheless, 
a number of approaches including the use of limited proteolysis [26] support a domain 
composition for CPS1 that mirrors that of Escherichia coli CPS, the only CPS for which 
the structure is known [27], notwithstanding the fact that these two enzymes have very 
important differences [13,21]. These differences include the chain composition (a single 
chain in CPS1; two subunits in E. coli CPS), the already indicated differences in the 
requirement for NAG, and the fact that CPS1 uses ammonia with high efficiency and 
cannot utilize glutamine as an ammonia source, whereas bacterial CPS uses ammonia 
poorly but utilizes glutamine as an internal ammonia source. The small subunit of the 
bacterial enzyme binds and cleaves the glutamine, channeling the resulting ammonia to 
the large subunit, where the entire carbamoyl phosphate synthesis reaction from 
ammonia takes place [21]. 
 As already mentioned, limited proteolysis and other studies support the 
similarity in domain composition and function of bacterial CPS and CPS1 (Fig. 1A). 
These studies evidenced [13,26,28] that CPS1 is composed of N- and C-terminal 
moieties of, respectively, ∼40 and ∼120 kDa, that correspond to the small and large 
subunits of E. coli CPS [12]. Since CPS1 uses no glutamine [10], no functions for the 
N-terminal ∼40-kDa moiety are known other than possibly some enzyme stabilization 
and activation [26,29]. In contrast, the ∼120 kDa moiety is known to host the catalytic 
and NAG-regulatory machinery [13,21], being composed of two ∼60-kDa halves, each 
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one of them consisting of an N-terminal ∼45-kDa phosphorylation domain followed by 
a ∼15 kDa domain [13]. Both phosphorylation domains are homologous [12]. The one 
in the N-half phosphorylates bicarbonate and the other in the C-half phosphorylates 
carbamate (Fig. 1B) [30,31]. The C-terminal ∼15-kDa domain (residues 1354-1500) of 
the C-half (the C-terminal domain of the enzyme) binds NAG and is crucial for 
activation, having been called the allosteric domain (ASD) [25,26,32], not hosting 
substrate sites or catalytic machinery. The other ∼15 kDa domain (precise mass, 17.7 
kDa; residues 822-973) connects both phosphorylation domains and its function is 
unclear since it has no substrate sites or catalytic components, having been called 
unknown function subdomain (UFSD) [26]. Interestingly, the UFSD has been found to 
host missense mutations in CPS1D patients (Fig. 1C,D) with rather high frequency [2], 
suggesting an important and until now unclear role of this domain.  
 CPS1D has been associated with a relatively large number of different, generally 
"private" mutations which occur in single families with very little recurrence [2]. Many 
of the >130 missense mutations reported in CPS1D remain to be proven responsible for 
the deficiency. The fact that they appear to be distributed non-homogeneously among 
the different gene exons even after correcting for the presence of CpG islands, suggests 
that some enzyme regions have a more important role on enzyme stability, folding or 
functionality than other regions, and that, therefore, mutations falling on these more 
important regions have higher repercussion than those falling in less critical regions of 
the protein. The UFSD domain, particularly its C-terminal half, may be such an 
important region since the relative occurrence of missense mutations (normalized per 
100 nucleotides) in exons 22 and 23, which encode most of the C-terminal half of the 
UFSD and which have no CpG islands, approximately doubles the relative frequency of 
these mutations for the entire coding sequence of the enzyme (p<0.01; χ2 test) [2]. 
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 We exploit here our recent ability to produce pure mature human CPS1, either 
wild-type or with the desired mutations, in a baculovirus/insect cell system [26], to 
examine the disease-causing potential of all known UFSD missense mutations (n=18) 
found in CPS1D patients [2,4,33-37] and to clarify the role and importance of the 
UFSD. When expression was possible, we studied the properties of the purified mutant 
enzyme forms, comparing them with wild-type human CPS1. Our findings support the 
disease-causing role of the mutations reported to affect the UFSD, revealing a key role 
of the UFSD for proper enzyme folding and for the regulatory cross-talk between NAG 
and phosphorylation sites. 
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2. Materials and Methods  
2.1 Patients and CPS1 Mutations 
 Table 1 lists 18 amino acid substitutions found in patients with CPS1D which 
are localized in the UFSD, giving some detail on the type of the clinical presentation in 
the patients carrying these mutations. Seventeen of the mutations were reported already 
[2,4,33-37], whereas one (mutation 13) is a novel change identified by one of us (J.H.) 
in a late onset CPS1D patient. We also report a patient with a neonatal presentation 
carrying an already reported mutation (p.Asp914His), a mutation for which there was 
no clinical information on the previously reported patient. In contrast, the new patient 
was known to have a neonatal presentation, indicating that the mutation was probably 
severe. The missense mutations in these two new patients were initially identified by 
mRNA studies in phytohemagglutinin-stimulated lymphocytes and then were confirmed 
by studies on genomic DNA as previously reported [37]. Samples were obtained with 
full informed consent of those entitled to give it, to perform molecular genetic 
diagnostics for clinical purposes. The PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) [38] and MutPred (http://mutpred.mutdb.org/) 
servers [39] were used to assess in silico the disease-causing potential of the different 
mutations. Amino-acid conservation was determined by ClustalW sequence alignment 
of either CPS1, CPSIII or other CPSs from 14, 6 and 24 species, respectively.  
 
2.2 Production of CPS1 carrying the desired mutation 
 The indicated mutations were introduced into pFastBac-CPS1 [26] using the 
overlapping extension method (Quickchange kit from Stratagene) and the forward and 
reverse primers given in Supp. Table S1. The correctness of the constructs, the presence 
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of the desired mutation, and the absence of unwanted mutations were corroborated by 
sequencing.  
 Human mature liver CPS1, either wild-type or carrying the desired mutation, 
with the N-terminal mitochondrial targeting sequence replaced by the 28-residue N-
terminal His6-tag, MSYYHHHHHHDYDIPTTENLYFQGAMDP, was expressed in a 
baculovirus/insect cell system and purified as previously described [26]. The same 
purification procedure (cell centrifugation, cell lysis, centrifugal clarification of the 
extract, Ni-affinity chromatography and centrifugal ultrafiltrative concentration [26]) 
was used for wild-type CPS1 and for the mutant enzyme forms. Protein in the final 
enzyme preparation was determined according to Bradford [40]. The CPS1 yield was 
determined from the total amount of protein in the enzyme preparation and the fraction 
of the protein corresponding to pure CPS1. The latter fraction was determined 
densitometrically from the band of approximately 163 kDa observed in Coomassie-
stained 8% polyacrylamide gels after SDS-PAGE [41]. For this purpose, stained gel 
images were collected with a Fujifilm LAS-3000 Imager using transmitted white light, 
and the fraction of the protein migrating in the CPS1 band of ∼163 kDa was determined 
with the Multi Gauge quantification software (from Fuji Film).   
 
2.3 Enzyme activity assays 
 CPS1 activity was assayed at 37ºC as carbamoyl phosphate production, 
monitored as citrulline by using OTC [26]. The standard assay mixture contained 50 
mM glycyl-glycine pH 7.4, 70 mM KCl, 1 mM dithiothreitol, 20 mM MgSO4, 5 mM 
ATP, 35 mM NH4Cl, 50 mM KHCO3, 10 mM NAG, 5 mM L-ornithine and 4 U/ml 
OTC. Specific activities refer to the pure enzyme (determined densitometrically, see 
section 2.2). When the concentration of a substrate was varied, other substrates were 
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kept at the concentrations given above, with MgSO4 being in 20 mM excess over ATP. 
Data for variable substrate or NAG concentration were fitted to hyperbolae using the 
GraphPad Prism program (GraphPad Software, San Diego, CA). One enzyme unit 
makes 1 μmol citrulline per minute. Specific activities refer to pure CPS1, estimated by 
densitometry (see above). 
  
2.4 Other assays 
 The thermal stability of CPS1 was monitored by incubating for 15 min at the 
specified temperature 0.5 mg protein/ml of the indicated CPS1 form (either wild-type or 
mutant), in a solution containing 50 mM glycyl-glycine pH 7.4, 2 mM dithiothreitol, 
10% glycerol, 0.5 M NaCl and 20 mM imidazole. At the end of the incubation the 
solution was rapidly cooled at 0°C and enzyme activity was determined immediately in 
the standard assay at 37ºC. 
 Western blotting was carried out after SDS-PAGE (section 2.2) as reported [26] 
using immunoluminiscent detection (Super Signal West Pico Chemiluminiscent 
Substrate, Thermo Scientific). 
 The previously reported [42] atomic structure model of CPS1 (based on the 
experimental crystal structure of E. coli CPS) was kindly provided by B. Barcelona 
(Instituto de Biomedicina de Valencia) and is used here for structural analysis of the 
mutations effects. Pymol (DeLano Scientific; http://www.pymol.org) was used for 
visual analysis, for structural superimposition and for depicting protein structures.  
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3. Results 
3.1. CPS1D mutations that affect the UFSD 
 Table 1 summarizes the 17 already reported [2,4,33-37] mutations reported in 
CPS1D patients that affect the UFSD, plus one more mutation (#13) falling in this 
domain which is reported here in a late onset patient. Thirteen of these mutations were 
found in patients with neonatal or with very severe presentations and thus might be 
expected to have drastic negative effects on CPS1 level or activity. Only mutations 4, 
13, 14, 16 and 17 were found exclusively in late onset patients or in patients without 
appropriate clinical information to judge about their severity. The fact that two 
mutations affecting the same residue were reported for Arg850, Gly911 and Asp914, 
three residues that are invariant among all CPSs, strongly supports a damaging role of 
the corresponding six mutations (p.Arg850Cys, p.Arg850His, p.Gly911Glu, 
p.Gly911Val, p.Asp914His, and p.Asp914Gly), in agreement with the predictions of the 
Polyphen-2 and MutPred servers (Table 1). In another patient with a neonatal 
presentation, the p.Leu843Ser and p.Lys875Glu mutations, both mapping in the UFSD, 
coexisted in the same allele [4]. Of these, the p.Leu843Ser mutation appears more likely 
to be disease-causing, because of the high conservation of Leu843 and because 
Polyphen-2 and MutPred give p.Leu843Ser a higher degree of probability and a higher 
score for having a damaging role than they do for p.Lys875Glu. The high residue 
conservation and the Polyphen-2 and MutPred server predictions also support the 
disease-causing nature of the p.Arg932Thr and p.Leu958Pro mutations, found in 
another two patients with neonatal presentations, whereas a disease-causing role appears 
less certain for the p.Ser913Leu, p.Ser918Pro and p.Gly964Asp mutations, found in 
other neonatal patients, since the residues affected are less conserved and the Polyphen-
2 and MutPred servers are non-unanimous in anticipating a disease-causing role (Table 
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1). The lack of unanimity in the predictions by both servers is possible, since they do 
not utilize the same traits [38,39] for assessing the disease-causing role of a given 
mutation. 
 The mutations p.Thr871Pro, p.Ile937Asn, p.Ala949Thr, p.Tyr959Cys and 
p.Tyr962Cys, reported in CPS1D patients with late presentations or with unreported 
presentation but with patient survival (suggesting less severe phenotype), affect 
invariant or virtually invariant residues and give high probability scores for being 
damaging in the Polyphen-2 and MutPred servers. Since the p.Ala949Thr mutation 
coexists with a null allele (p.Tyr89*) in the patient [2], it cannot abolish enzyme activity 
since otherwise the patient would have had a neonatal presentation. In principle, the 
same can be said for the p.Ile937Asn mutation, given the fact that the other CPS1 allele 
found in the same patient corresponds to a very severe splice site aberration that should 
lead to exon 27 skipping, with frameshift and truncation. Since in this patient the CPS1 
allele hosting the p.Ile937Asn mutation also hosts a second missense change, 
p.Gly401Arg (Table 1), this second change cannot be expected to be highly deleterious 
either. In contrast, a drastic effect is likely for the p.Thr871Pro mutation since it 
coexists in the patient with the expectedly mild mutation (given the mildness of the 
substitution), p.Glu1194Asp [37].  
 
3.2. UFSD mutations negatively influence the yield of CPS1 
 We previously used the baculovirus/insect cell system utilized here for 
producing twenty CPS1 forms carrying different missense changes identified in CPS1D 
patients and spread all over the CPS1 protein except the UFSD [26,43]. We also 
reported [25] the effects of another five non-CPS1D-associated but functionally 
important mutations affecting the C-terminal domain (ASD). Furthermore, in 
13 
 
unpublished studies, we have monitored the effects of ten more mutations (nine in the 
ASD) of which five had been identified in patients. Only three among these 35 
experimentally tested mutations compromised drastically recombinant CPS1 production 
([26], and data not shown). The present UFSD mutations yield an entirely different 
picture (Fig. 2A). Recombinant production of CPS1 protein was virtually abolished by 
six mutations and it was decreased 85-95% and ~75% by five and four mutations, 
respectively. Only for three of the eighteen mutations studied here (p.Arg850Cys, 
p.Arg850His and p.Ala949Thr) the yield of pure CPS1 was comparable to that of the 
wild-type enzyme. Interestingly, each one of the two mutations found in the same allele 
of one patient, p.Leu843Ser and p.Lys875Glu (Table 1), reduced the yield of CPS1 by 
nearly 90% (Fig. 2A), raising the possibility that their joint presence in the same protein 
molecule might reduce further CPS1 production. 
 The low yields observed with most mutants appear to be due to poor CPS1 
polypeptide production and to gross misfolding. Thus, SDS-PAGE of the pellet (Fig. 
2B, P) and the supernatant (Fig. 2B, S) obtained by centrifugation of the initial cell 
extract not only revealed for most mutants decreased CPS1 levels, but also showed that 
the CPS1 present tended to appear in the precipitate. Furthermore, a multiplicity of 
bands of lower molecular weight than complete CPS1, corresponding to CPS1 
degradation products, were revealed by western blotting in the precipitates of these low-
yield mutants (Fig. 2C). 
 In summary, the majority of the mutations found in CPS1D patients that affect 
the UFSD appear to disturb CPS1 folding and to enhance CPS1 degradation. The drastic 
decrease in enzyme production should be disease-causing at least for the seven 
mutations that reduce enzyme production by >90% (p.Thr871Pro, p.Gly911Glu, 
p.Gly911Val, p.Asp914His, p.Asp914Gly, p.Ser918Pro and p.Gly964Asp; Fig. 2A). 
14 
 
Indeed, six of these mutations were found in patients with neonatal or very severe 
presentations, and the other mutation (p.Thr871Pro), although found in a late onset 
patient, coexisted with an expectedly mild second allele and is likely to have by itself a 
severe effect (Table 1). On the other hand, the two mutations found in late onset patients 
that were anticipated to be mild (see section 3.1), p.Ala949Thr and p.Ile937Asn, were 
associated with substantial or normal yield of CPS1 (Fig. 2A).  
 
3.3. Eight UFSD mutations strongly impair CPS1 activity 
 Although with most mutations little soluble CPS1 was produced, we always 
carried out the complete CPS1 purification protocol, observing by SDS-PAGE of the 
final preparation, with all the mutants (Figs. 2D,E), a 163 kDa-band corresponding to 
soluble CPS1 (confirmed by western blotting, data not shown). However, the purity of 
CPS1 decreased with the yield, being <10% of the protein (densitometric estimation) for 
the mutants with the lowest yield (Figs. 2D,E). Despite the presence of the CPS1 band, 
CPS1 activity was very low in the final preparations of the mutants p.Thr871Pro, 
p.Gly911Glu, p.Gly911Val, p.Asp914His, p.Asp914Gly, p.Ser918Pro, p.Leu958Pro and 
p.Gly964Asp. The estimated specific activity of pure soluble CPS1 was ≤6% of wild-
type for six of these mutations and ≤12% for the other two (Fig. 3A). Assuming that the 
mutation-induced misfolding causes similar decreases in the production of soluble 
CPS1 protein in insect cells and in the liver, the low yields (Fig. 2A), combined with the 
decreased activities (Fig. 3A), lead to an expectation of very low residual activities in 
the liver (<1% of normal for homozygosity) for any of these eight mutant forms. The 
low residual activity further supports the disease-causing nature of these mutations and 
agrees with their observation in neonatal or very severely affected patients (Table 1). 
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Only the p.Thr871Pro mutation was observed in a late onset patient, but, as already 
indicated, the second allele in this patient was expectedly mild (p.Glu1194Asp) .  
  
3.4. Activity and stability changes with another eight UFSD mutations 
 Eight of the ten mutations not dealt with in section 3.3 generally were associated 
with less drastic but substantial decreases in specific activity, and/or with decreased 
thermal stability of the enzyme (Fig. 3). Among these mutations, p.Ile937Asn caused 
the largest specific activity decrease (~90% decrease) (Fig. 3A), which combined with 
the observed 75% reduction in yield (Fig. 2A), would result (making the already 
indicated assumption that the yield in insect cells grossly corresponds to the yield in the 
liver) in ∼3% residual activity for homozygosity, supporting disease-causation. 
Nevertheless, the role of the other mutation found in the same allele (Table 1), 
p.Gly401Arg, remains to be determined, although this mutation maps in the CPS1 N-
terminal region of unknown function (Fig. 1) which hosts few CPS1D mutations [2], 
and it is predicted by Polyphen-2 and MutPred as benign or as having little probability 
of being disease-causing (not shown). 
 In the other case (Table 1) in which the same allele carried two missense 
mutations, p.Leu843Ser and p.Lys875Glu, the first of these mutations decreased activity 
by ∼70% (Fig. 3A) and both mutations reduced ~90% the yield of CPS1, leading to the 
assumption of a liver activity of ∼3% of normal for a null second allele (the case in the 
patient carrying these mutations [2]). This estimate might be optimistic considering the 
already mentioned possibility that the joint presence of both mutations in the same 
CPS1 polypeptide chain could reduce even further proper folding and CPS1 production, 
and also because the p.Lys875Glu mutation substantially decreased CPS1 thermal 
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stability (Fig. 3B). In summary, the data for this patient appear to account fully for its 
neonatal presentation. 
 Decreased thermal stability appears a major determinant of the effects of the 
p.Ala949Thr and p.Tyr959Cys mutations (Figs. 3B,C), being the only important 
aberration observed for the first of these two mutations. Thus, p.Ala949Thr was not 
associated with decreased yield (Fig. 2A) or with a large specific activity decrease (Fig. 
3A), but it lowered the half-inactivation temperature of the enzyme by ∼8ºC (Fig. 3C), 
bringing it down to nearly 40ºC, which is close to the physiological body temperature, 
leading to the expectation of an important reduction in enzyme half-life and thus of 
enzyme level in the tissue. Nevertheless, some residual activity should be expected, 
agreeing with the late onset presentation in the patient carrying this mutation (the other 
allele carried a null mutation, Table 1). A similar degree of reduction in thermal stability 
was also observed for the p.Tyr959Cys mutation (Fig. 3B,C). However, in this case the 
mutation also decreased importantly CPS1 yield (by 75%; Fig. 2A) and specific activity 
(by 70%; Fig. 3A), with the resultant final activity in the tissue possibly being decreased 
further by the accelerated thermal inactivation. The late onset presentation in this patient 
(Table 1) could be due to the residual activity from this mutation, together with that 
resulting from the mutation carried in the second CPS1 allele (p.Pro1462Arg), which is 
not inactivating (our own unpublished data). 
 Although the p.Tyr962Cys mutation only reduced ∼50% the specific activity of 
the soluble enzyme (Fig. 3A) without substantially decreasing thermal stability (Fig. 
3B), it decreased ∼75% CPS1 yield (Fig. 2A). The combination of these two detrimental 
effects might result in an activity in the tissue of ~6% of normal, provided that the 
second CPS1 allele found in the patient carrying this mutation (p.Ile632Arg; #17, Table 
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1), which affects the bicarbonate phosphorylation domain, is inactivating. This residual 
activity would explain that patient #17 is alive. 
 The patients with the p.Ser913Leu or p.Arg932Thr mutations had neonatal 
presentations (Table 1) that must reflect a cumulative effect of modest to drastic but not 
extreme changes in yield or specific activity of CPS1 caused by these mutations. Thus, 
the p.Ser913Leu mutation decreased CPS1 yield and specific activity, respectively, to 
∼20% and ∼30% of normal, and the p.Arg932Thr mutation caused respective decreases 
to ~12% and 40% of normal (Figs. 2A and 3A). A residual liver activity of ∼3% of 
normal is conceivable for both mutations, if they coexist in the patients with null second 
CPS1 alleles. 
 
3.5. Km effects are the major changes associated with mutations affecting Arg850. 
 Changes in yield (Fig. 2A), specific activity (Fig. 3A) or thermal stability (Fig. 
3B) cannot account for the neonatal presentations observed in the two patients that 
carried mutations affecting Arg850, since for the p.Arg850His and p.Arg850Cys 
mutations thermal stability was essentially normal and the yields and specific activities 
were at least ∼50% and ∼25% of normal, respectively. However, since the specific 
activity assay used here utilizes saturating (for the wild-type enzyme) substrate 
concentrations, there might be room for Km or Ka effects that could have negative 
consequences on enzyme activity at the generally low substrate concentrations present 
in the tissue [44,45]. This is certainly the case for the p.Arg850Cys mutation, which 
exhibits ∼5-fold and ∼3-fold increases in the Km values for ATP and bicarbonate, 
respectively, and, even more importantly, a ∼18-fold increase in the Ka value for NAG 
(Fig. 4A-C,E,G). Similarly, in the case of the p.Arg850His mutation the Km for ATP 
and the Ka for NAG were increased 3-fold and 10-fold, respectively (Fig. 4A,B,F). 
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Although these kinetic constant changes are not large enough to decrease importantly 
the activity observed in the standard assay, they can lead to drastic reductions in the 
CPS1 activity in vivo, since, for example, NAG may be far from saturating even for the 
wild-type enzyme [17-19,44,45], and thus, much less saturating for these mutant 
enzyme forms. 
 Among the ten UFSD mutants in which CPS1 yield and activity permitted 
kinetic analysis (Figs. 4A-D), substantial Km or Ka changes were rarely observed. In 
addition to the already indicated changes in the two mutants of Arg850, the p.Ile937Asn 
mutation modestly increased the Ka value for NAG (Fig. 4A) and the Km for ammonia 
(Figs. 4D,H), and the p.Leu843Ser and p.Ser913Leu mutations increased the Ka for 
NAG (Fig. 4A). It is interesting that the Ka for NAG was increased in all cases that 
exhibited a kinetic change, suggesting a role of the UFSD in the cross-talk known to 
exist between the NAG site and the catalytic machinery of the enzyme [15,23]. In 
summary, while Km or Ka changes do not appear to play a paramount role in decreasing 
enzyme activity with most UFSD mutants, they certainly do so with the two mutations 
affecting Arg850, for which they appear major determinants of the severe deficiency 
observed in the patients carrying these mutations. 
 
3.6. UFSD mutations generally decrease Vmax of the enzyme 
 With those mutations in which kinetic analysis was possible, it was observed 
that, except in the case of p.Lys875Glu, the mutations modestly decreased Vmax (Fig. 
5A) in a proportion that was similar to the decrease in specific activity (Fig. 3A). This 
was to be expected if the mutations affect mainly kcat without producing very large Km 
effects, since the standard activity assay utilizes saturating (for the wild-type enzyme) 
concentrations of the substrates and of NAG. A plot of specific activity versus Vmax 
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(Fig. 5B) could be reasonably adjusted to linear regression passing through zero. This 
suggests that the very low activity of the mutants that were very little expressed and 
that, therefore, were not amenable to kinetic analysis, could be due to a Vmax effect. 
Thus, the UFSD domain appears to influence the rate at which the enzyme catalyzes its 
complex, three-step reaction.   
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4. Discussion 
 The present results validate the baculovirus/insect cell expression system [46] 
for monitoring the consequences of CPS1D mutations. Such system is already the 
standard for the same task in Gaucher's disease [47,48] and has been used with other 
diseases [49-52]. It associates the abundant expression and possibility of purification 
that characterizes E. coli expression, with a high compatibility with human proteins, 
which frequently cannot be expressed in bacteria [46]. In the case of Gaucher's disease, 
the large experience (exemplified in [47, 48]) attests the concordance of the results in 
this expression system with the clinical phenotype. This concordance was prospectively 
proven with two polymorphisms of methylenetetrahydrofolate reductase [50], since the 
one (p.Ala222Val) shown to have negative effects on the enzyme when using 
baculovirus/insect cells, was later on proven by epidemiological and genome-wide 
association studies to be linked to increased plasma homocysteine levels [53]. Our 
experience with CPS1 also supports the faithfulness of this system in revealing the 
impact of CPS1 mutations. Thus, in our prior studies [26] two CPS1 polymorphisms 
believed to be trivial had no substantial effect on any CPS1 trait investigated (activity, 
stability, kinetic constants, gross estimation of yield), whereas two mutations affecting a 
catalytic domain and used as positive controls were strongly detrimental. Furthermore, 
the results with three CPS1D-associated mutations affecting the glutaminase-like 
subdomain (GSD) (Fig. 1A) of unknown function and of three additional mutations 
affecting the allosteric domain (ASD, Fig. 1A) accounted for disease-causation because 
of impaired activity, stability or NAG activation. These results, which followed earlier 
pilot studies using baculovirus/insect cell-expressed rat CPS1 (a surrogate of human 
CPS1) [43], are extended now with those for 18 mutations affecting the UFSD. 
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 The present results confirm that the seventeen mutations reported earlier [2,4,33-
37] and the one described here that affect the UFSD of CPS1 in patients with CPS1D 
are disease-causing. The observed effects of the mutations on the production, activity, 
thermal stability and kinetic constants of the recombinant enzyme match in most cases 
the severity of the clinical presentation. Our data illustrate in one case the fact that each 
one of two missense changes in the same allele (p.Leu843Ser and p.Lys875Glu) has a 
detrimental effect on the enzyme, raising the possibility that their combined presence in 
the same protein molecule could be even more detrimental.  
 A clear conclusion of our studies is that, at least for this domain and with this 
eukaryotic expression system, the determination of the yield of CPS1 protein is a key 
element in judging the disease-causing role of each mutation. We clearly show that the 
abolition or the drastic decrease of CPS1 production is a crucial mechanism of disease 
production by many missense mutations affecting the UFSD. Our findings point to 
decreased efficiency of proper folding as a key determinant of the poor production of 
the soluble protein. Although there are few in vitro expression studies for CPS1 
[25,26,29,43], our prior investigations with 35 missense mutations mapping in other 
domains (with a predominance of mutations affecting the C-terminal ASD) do not 
highlight poor CPS1 production as a key determining element of the effects of the 
mutations affecting these other protein regions, since only with ∼10% of the mutations 
was CPS1 production hampered or abolished. It therefore appears that a decrease in the 
efficiency of proper CPS1 folding is a characteristic and remarkable trait of CPS1D-
associated mutations affecting the UFSD. Such trait may be the reason for the 
prominence of this domain in CPS1D, where missense mutations have been found in 
relatively high density [2]. 
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 The central position in the enzyme architecture and the intimate relations of the 
UFSD with other CPS1 domains [2,27,42] may account for the particular impact of the 
mutations affecting this domain on CPS1 folding. In the existing structural CPS1 
models [2,42] based on the E. coli CPS structure [27], the UFSD makes very extensive 
contacts with both phosphorylation domains and, to a lesser extent, with the N-terminal 
moiety of the enzyme (the small subunit-like region) (Figs. 1C,D). This L-shaped 
domain (Fig. S1A) which embraces between its two arms the C subdomain of the 
bicarbonate phosphorylation domain (Fig. S1D), is sandwiched between the small 
subunit-like N-terminal moiety and the carbamate phosphorylation domain, two 
domains that lie respectively on top and below the plane defined by this L (Fig. 1D, 
right panel). Therefore, mutation-triggered UFSD misfolding can be expected to result 
in distorted relations between these other protein domains. The CPS1D-associated 
mutations affecting this domain cluster in the regions of interaction of the UFSD with 
other domains rather than in the exposed regions (Fig. 1D) that are involved in 
intermolecular interactions [27]. Therefore, the distribution of the mutations does not 
support the possibility of an increase in the interactions between the UFSDs of different 
enzyme molecules as the cause for the decreased solubility observed with many of these 
mutants. This agrees with our observation with E. coli CPS that the UFSD is not 
involved in dimer formation [54], and with our finding that human CPS1 exists mainly 
as monomers [10,26].  
 A detailed structural rationalization of the effects of the mutations studied here is 
included as Supplementary material. In summary, our results highlight a paramount 
integrating role of the UFSD for building the highly complex CPS1 architecture, 
revealing the key organizing function of this domain, and exemplifying the importance 
of this core structural element despite its lack of substrate binding and catalytic 
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machinery. Interestingly, a recent in silico study already proposed for this domain a key 
structural role in CPS1 [55]. On the basis of such key function of this domain, which is 
conserved in all forms of CPS (including the archaeal types, in which the C-terminal 
moiety is split into two complementary regions encoded by different genes), we would 
propose to call it in the future the "Integrating Domain" of CPS1. Our data fully account 
for the important representation of this domain in the database of missense mutations 
found in CPS1D [2], revealing that the main effects of the mutations in this domain are 
to negatively affect global CPS1 folding and architecture. We also document for some 
mutations and propose for other mutations that they have effects of greater or lower 
magnitude on the Vmax of the enzyme. This effect could be due to gross defects on 
domain architecture, that, for example, could block the conduit of the activating 
allosteric NAG signal, or the tunnel [27] through which intermediates must flow 
between both phosphorylation centers; or it could derive from more subtle changes such 
as the hampering of the concerted opening [56,57] of the B subdomains of both 
phosphorylation domains to allow product release. Indeed, mutations in the UFSD could 
be in the signaling path between both phosphorylation centers since the UFSD contacts 
the B domain of the carbamate phosphorylation domain, which is believed to trigger the 
concerted opening [57], and it also contacts the active site of the bicarbonate 
phosphorylation domain, which is to be opened (Fig. 1D). Similarly, the UFSD appears 
to be involved in the cross-talk between the NAG site and the catalytic centers, since 
some UFSD mutations increase the Ka for NAG. Full understanding of this involvement 
will have to await the determination of the structural mechanism of NAG activation of 
CPS1. 
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Legends to Figures 
 
Fig. 1. Domain composition, function and architecture of CPS1. (A) Schematic linear 
representation in the CPS1 polypeptide of the different domains. The grey-shaded 
background bars schematize the 40-kDa N-terminal and the 120-kDa C-terminal 
moieties of the enzyme that correspond to the small and large subunits of E. coli CPS, 
respectively. The colored bars represent the different CPS1 domains as defined from 
sequence alignment with E. coli CPS. Their approximate masses, in kDa, and the 
domain start/end residue numbers are given, respectively, above and below each 
domain. The N-terminal mitochondrial targeting peptide that is removed upon 
internalization in the organelle is not represented. The domains are defined by their 
function (when known; ?, function unknown), showing below each of them the 
corresponding acronym (ISD, GSD, BPSD, UFSD, CPSD and ASD) as defined in [2]. 
(B) Reactional steps of the CPS1 reaction, shown under the domain catalyzing it, 
colored as the domain. The thick empty horizontal black arrow denotes the migration of 
carbamate from the bicarbonate phosphorylation site to the carbamate phosphorylation 
site. (C) Stereo view of structural model of Cα trace of human CPS1 [42]. Each domain 
is colored differently and labeled in the same color. In the UFSD, the spheres mark the 
residues (numbered) hosting extremely drastic (red) or less drastic (blue) mutations 
found in CPS1D patients. Both ATP molecules and essential K+ ions are placed in their 
sites by superimposition of the E. coli CPS structure (Protein Databank file 1BXR; 
[48]). (D) Relations of the UFSD with other domains. Two views of the domain 
(cartoon representation, in yellow) are shown, highlighting the residues hosting the 
mutations (red and blue spheres as above) illustrating that the mutations cluster at the 
regions of contact with the other domains (labeled). Only the parts of these other 
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domains that contact the UFSD are shown, in surface representation, colored as in (A). 
In the right panel the ISD is shown as transparent surface to allow visualization of 
Ala949, which is clamped between the ISD, the GSD and the BPSD.  
 
Fig. 2. Effects of UFSD domain mutations on CPS1 production. WT, wild-type 
recombinant enzyme. Mutations are represented in single-letter code. Arrowheads 
signal the position of the CPS1 band. (A) Yield of pure CPS1 protein (total protein × 
CPS1 purity determined densitometrically from Coomassie-stained SDS) per liter of 
cell culture, relative to the mean yield of pure wild-type CPS1 (2.7 mg/L cell culture). 
(B) Distribution of protein between the insoluble, P, and the soluble, S, fractions of the 
initial extracts of cells expressing the wild-type enzyme or the indicated mutants, 
analyzed by SDS-PAGE and Coomassie staining. The samples applied to each track 
correspond to identical volumes of original cell extract. (C) Western blotting and CPS1 
immunostaining in the precipitates from the cell extracts for the indicated enzyme 
forms. (D, E) Coomassie-stained SDS-PAGE of the preparations obtained after 
purification of the wild-type and the different mutant enzyme forms as indicated. St, 
protein markers, with masses, in kDa, indicated at the side.  
 
Fig. 3. Enzyme activity (A) and thermal stability (B, C) of wild-type or mutant forms of 
CPS1. The activity per mg of pure CPS1 is expressed relative to the corresponding 
activity of the pure wild-type enzyme (2.3 U/mg). (B,C) Fraction (as percentage) of the 
activity remaining for the indicated enzyme form after 15-min heating either at 46ºC (B) 
or at the indicated temperatures (C). 
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Fig. 4. Effects of UFSD mutations on the Km values of CPS1 for its three substrates and 
on the Ka value for NAG. (A-D) Histograms illustrating the changes in Km or Ka values 
for the indicated CPS1 mutants and substrates or NAG, relative to the corresponding 
values for the wild-type enzyme. The curves on the right panels (E-H) illustrate the 
dependency of the reaction velocity on the concentration of each substrate or NAG for 
the wild-type enzyme or for the indicated mutants. 
 
Fig. 5. Influence of UFSD mutations on Vmax values for CPS1 activity. (A) Changes in 
Vmax values for the different mutants, as a fraction of the value for wild-type CPS1. (B) 
Plot of the specific activity for each mutant as a function of the Vmax for this same 
mutant. Relative values with respect to wild-type are given for both parameters. The 
regression line goes virtually through zero and gives a value of r2=0.842. 
 
Table 1. CPS1 missense mutations mapping in the UFSD, found in CPS1D patients 
 
Amino acid in 
CPS 
MutPred 
prediction
Mutation 
#  
Amino acid 
changea 
Presentation Report
1 III Other 
PolyPhen-2 
prediction 
g-score 
1 p.Leu843Serb Neonatal [4] L/M L L/i/a Probably damaging 0.92 
2 p.Arg850Cys Neonatal [35] Probably damaging 0.98 
3 p.Arg850His Neonatal [2,33,37]
R R R 
Probably damaging 0.98 
4 p.Thr871Pro Late.  
2nd allele: p.E1194D
[37] T T T/s Probably damaging 0.86 
5 p.Lys875Glub Neonatal [4] K K Variab. Possibly damaging 0.84 
6 p.Gly911Glu Neonatal [2] Probably damaging 0.87 
7 p.Gly911Val Neonatal [34] 
G G G 
Probably damaging 0.97 
8 p.Ser913Leu Neonatal [2] S S S/a/g/d Probably damaging 0.79 
9 p.Asp914His Pat. 1:Unknown 
Pat. 2c: Neonatal 
[2] 
Present Probably damaging 0.95 
10 p.Asp914Gly Hyperammonemia, 
seizures. Homozyg.d
[2] 
D D D 
Probably damaging 0.92 
11 p.Ser918Pro  Neonatal [33] S/G G A/s/e Benign 0.93 
12 p.Arg932Thr Neonatal [2] R R R/k Probably damaging 0.93 
13 p.Ile937Asn Late.e   Present I I I/V/L Probably damaging 0.83 
14 p.Ala949Thr Late.d  
2nd allele: p.Y89* 
[2] A A A/G Probably damaging 0.89 
15 p.Leu958Pro Neonatal [34] L L L/M/F/
Y 
Probably damaging 0.94 
16 p.Tyr959Cys Unknown. Alived 
2nd allele: p.P1462R 
[2] Y Y Y Probably damaging 0.94 
17 p.Tyr962Cys Unknown. Alived 
2nd allele: p.I632R 
[2] Y Y Y/f Probably damaging 0.92 
18 p.Gly964Asp  Neonatal [36] G G Variab. Probably damaging 0.37 
 
Thin horizontal lines separate mutations affecting different amino acids. Unless indicated below, 
cDNA changes are to be found in [4,5,7]. Amino acids are shown in three-letter code for the mutant 
allele found in the UFSD, and in one-letter code for the second allele and for occurrence in the 
various CPSs, being in low case when found with low frequency. Variab. denotes the occurrence at a 
given position, in the indicated groups of CPSs, of >4 types of amino acids with no constant chemical 
characteristics (polar, apolar, charged, etc.). PolyPhen-2 grades the probability of a damaging effect 
of an amino-acid substitution, from higher to lower, as Probably damaging, Possibly damaging, and 
Benign. MutPred gives a g score corresponding to the probability that a given amino-acid substitution 
was deleterious/disease-associated. 
aTranslation of the cDNA reference sequence NM_001875.4 (GenBank). Nucleotide 136 
in this sequence is considered +1, since it is the A of the translation initiation codon.   
bThe changes p.Leu843Ser and p.Lys875Glu coexisted within the same allele. 
cNovel patient. The cDNA change is c.2740G>C, the same found in the previously 
reported patient with this amino acid change [4]. 
dUnkown when originally reported.  New data gathered on the patient. 
eNovel patient. The cDNA change is c.2810T>A. The changes p.Ile937Asn and 
p.Gly401Arg (c.1201G>C) coexisted within the same allele. The second allele carries the 
mutation c.3337 -3T>A/ c.3337 -2A>T, which should lead to exon 27 skipping, frameshift 
and premature termination.  
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Fig. S1. Mapping of the clinical 
mutations of the UFSD domain in 
the structural model of CPS1. The 
figures are in cartoon representation. 
Residues that host clinical mutations 
are shown either as red (drastic) or 
blue spheres (less drastic), or 
detailing the side-chains (in blue-
colored sticks). Residues are labeled 
in single letter code. CPS1 domains 
and secondary structure elements of 
the UFSD are labeled (from N- to C-
terminus, α1 to α7; and β1 to β2). 
(A) Mapping of the mutations in the 
structural model of the isolated 
UFSD. (B-D) Details of the three 
regions of the UFSD that host 
clinical mutations, illustrating their 
relations with elements of the 
neighboring domains. In (C) the 
broken lines mark the ion pair 
network involving Asp914, Arg932 
and Tyr962 that is lost when any of 
these three residues is mutated.  
 
